Leadership

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

Starboard Value has reportedly bought a $1bn stake in Pfizer with an ambition to turn the big pharma around. But growth, not cost cuts, are Pfizer’s challenge.

​​​<p>Executive Summary​​ </p> ​​<br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>

​​​<p>Executive Summary​​ </p> ​​<br> <p>Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements</p>

In this week's podcast edition of Five Must-Know Things: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark’s shifting revenues.

Recent moves in the industry include C-suite shuffle at Perspective Therapeutics and Bausch Health, plus Oculis Holding gets a new CDO and Tiziana Life Sciences gets a new CEO.

The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.

Recent moves in the industry include changes at the top for Xilio Therapeutics, Zentalis Pharmaceuticals, Beam Therapeutics and Cipher Pharmaceuticals, plus Ardelyx gets a new chief commercial officer.

Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.

Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.

Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.

As it reported mixed second-quarter earnings, South Korea's pharma industry is increasingly turning to obesity pipeline assets. Meanwhile, leadership disputes among family members within Hanmi are resurfacing.

Recent moves in the industry include C-suite shuffles at Valeo Pharma, Xeris Biopharma, ALX Oncology and MEI Pharma, plus BeiGene and Phio Pharmaceuticals get new chief financial officers.  

Recent moves in the industry include C-suite shuffle at Nkarta, plus I-Mab gets a new CEO.  

Merck & Co.’s $16.11bn in sales exceeded expectations and prompted a slight increase in 2024 guidance, but HPV vaccine Gardasil came in slightly below consensus due to lower sales in China.

Despite initial promise, a novel autologous cell transplant therapy for severe heart failure has faced multiple challenges in gaining full approval in Japan, potentially providing learnings for other developers of regenerative medicines.

Recent moves in the industry include C-suite shuffles at Pulmatrix, Intellia Therapeutics and BridgeBio, while Akeso got a new chief financial officer from Cellectis.